July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Antifibrotic effect of conbercept (KH902) on human tenon’s fibroblasts
Author Affiliations & Notes
  • Shaodan Zhang
    The Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, China
    Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China
  • Lin Du
    Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China
  • Di Wu
    Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China
  • WAI KIT CHU
    Departments of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, HONG KONG, Hong Kong
  • Hailin Wang
    Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China
  • Chi Liu
    Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China
  • Footnotes
    Commercial Relationships   Shaodan Zhang, None; Lin Du, None; Di Wu, None; WAI KIT CHU, None; Hailin Wang, None; Chi Liu, None
  • Footnotes
    Support  Scientific research project of Shenyang Municipal Health and Family Planning Commission (2015-2018)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 476. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shaodan Zhang, Lin Du, Di Wu, WAI KIT CHU, Hailin Wang, Chi Liu; Antifibrotic effect of conbercept (KH902) on human tenon’s fibroblasts. Invest. Ophthalmol. Vis. Sci. 2018;59(9):476.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the effect of conbercept (KH902) on the proliferation, migration, extracellular matrix production, and cytokine secretion of the human tenon’s fibroblasts (HTFs).

Methods : Human tenon’s tissue was obtained from adult strabismus patients during surgery. Primary cell culture for the HTFs was performed. Conbercept at 100ug/mL were administered for 24h in 10% serum conditions. The effect of conbercept on HTFs proliferation and cell viability was determined using MTT assay. Scratch wound assay was performed to evaluate the cell migration. The mRNA expressions of MKI67, alpha smooth muscle actin (a-SMA), fibronectin, collagen type I and caspase 3 were assessed by quantitative real-time PCR. Cell supernatants were tested for the concentrations of secreted VEGF, monocyte chemotactic protein (MCP)-1, fibroblast growth factor (FGF-b), tumor necrosis factor-a (TNF-a), interferon gamma (IFNγ), and platelet-derived growth factor-BB (PDGF-BB) using multiplex bead analysis.

Results : Conbercept at 100ug/mL slightly reduced the cell viability in cultured HTFs (93.72% of control) and had no effect on the cell migration. MRNA expression of MKI67, a-SMA, fibronectin and collagen I was significantly downregulated by conbercept. The level of caspase 3 mRNA in conbercept treated HTFs had no difference with the controls. The concentrations of secreted VEGF (t=3.962,p=0.011), FGF-b(t=4.735,p=0.005), TNF-a(t=4.293,p=0.008) , and IFN-γ (t=2.796,p=0.038) were significantly lower in Conbercept treated cell supernatants compared with untreated controls.

Conclusions : Conbercept could effectively downregulate the fibrosis-related mRNA and protein expression in HTFs with no obvious effects on the cell proliferation and migration. It may be used as an independent or complementary anti-fibrotic agent to other antimetabolites in glaucoma filtering surgery.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×